A fast-tracked Parkinson's disease treatment received permission this week to proceed with a Phase 2 clinical trial.
GAD, or glutamic acid decarboxylase, is an experimental treatment injected into the brains of people with Parkinson's. In early studies it appears to help calm some of the tremors and other disruptive activities associated with Parkinson's disease.
Study sites in the United States will begin enrolling patients in the coming weeks. The randomized, blinded study will take place at up to ten centers across the United States, and will enroll approximately 44 subjects with advanced Parkinson's disease.
The goal of the Phase 2 clinical trial is to further measure safety of the gene transfer therapy and to confirm the initial effectiveness reported in the Phase 1 clinical trial.
Source:
Neurologix, Inc. news release, received by e-mail March 27, 2008